The Russian Direct Investment Fund and Hyderabad-based Hetero Biopharma have signed a pact to produce over 100 million doses of Sputnik V vaccine a year. Phase 3 clinical trials of the Sputnik V are approved and ongoing in Belarus, the UAE, Venezuela and other countries, and Phase 2/3 have been approved in India. The production will begin from 2021.
AstraZeneca will likely to conduct another round of global trial of the Oxford vaccine to determine the level of protection. The CEO of the company said that the questions arose over vaccine’s level of protection during the current studies demanded the new trial. The new trial would be run instead of adding an arm to an ongoing US trial, the CEO added.
The oral antiviral drug Favipiravir has reportedly been found safe and effective for mild to moderate COVID cases. The drug has been approved by Japan and China for COVID treatment. A study published in the International Journal of Infectious Diseases claimed that the early treatment with favipiravir might be associated with more rapid viral clearance.
The Lucira Health developed single-use self-testing kit has got the US Food and Drug Administration approval for home use. The kit will provide results in 30 minutes from the nasal swab samples of individuals aged 14 and above. The single-use test is said to be the first that can be fully self-administered and provide results at home.
The Tata Group launched COVID-19 test kit is said to have offered a speedy detection of virus attack, faster than the global standard RT-PCR method. The TataMD CHECK, jointly developed by the Govt, uses nasal swab and is said to be more accurate than the rapid antigen test currently used widely in India.
NASA had a successful landing of its Osiris-Rex spacecraft on the surface of asteroid Bennu. The spacecraft will collect a handful of cosmic rubble for analysis back on Earth. Scientists hope that in a week they could get information on how much Osiris-Rex grabbed. If successful, Osiris-Rex will return the samples in 2023.